Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

Luye Group

Other names: Yantai Patronus Biotech | Yantai Patronus Biotech Co., Ltd. | Yantai Patronus Biotech Co., Ltd | Yantai Patronus Biotech Co. Ltd. | Yantai Patronus Biotech Co. Ltd | Luye Pharma | Luye Pharma Group | Nanjing Luye Sike Pharma | Nanjing Sike Pharma | Sichuan Baoguang Pharma | Luye Group Ltd | Vela Diagnostics | Luye Life Sciences Group | Luye Pharma USA Ltd. | Luye Pharma Group Ltd | Luye Pharma Group Ltd. | Sichuan Baoguang Pharmaceutical | Sichuan BAOGUANG Pharmaceutical Co. Ltd. | Sichuan BAOGUANG Pharmaceutical Co., Ltd. | Nanjing Luye Sike Pharmaceutical Co., Ltd. | Nanjing Luye Sike Pharmaceutical | Nanjing Luye Sike Pharmaceutical Co Ltd | Vela Diagnostics Pte. Ltd. | Boan Biotech
Related tests:


Vela Diagnostics launches focused (60 genes) and comprehensive (525 genes) NGS-based pan-cancer panels (VelaDx Press Release)
"Vela Diagnostics announced today the launch of its new OncoKey® SL 60 and 525 Plus Panels. These next-generation sequencing (NGS)-based panels are intended for detection of DNA and RNA cancer biomarkers from formalin-fixed paraffin-embedded (FFPE) tissue specimens, for up to 64 samples in a single sequencing run."
OncoKey™ SL 525 Plus Assay • OncoKey™ SL 60 Plus Assay
Vela Diagnostics announces collaboration with the National Cancer Centre of Singapore to refine novel cancer therapy (VelaDx Press Release)
"Vela Diagnostics announced a collaboration with the National Cancer Centre of Singapore (NCCS) to develop a molecular diagnostic assay to predict individual patients’ responses to a cancer therapy called Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs). Being able to predict an individual’s response will help clinicians determine if EGFR-TKIs are a suitable therapeutic option for the patient. The partnership between Vela Diagnostics and NCCS aims to refine the therapeutic management of cancer to improve clinical outcomes...The next phase of the collaboration will evaluate the efficacy of the assay through a clinical trial to test the response of patients to EGFR-TKIs."
Licensing / partnership
NDA filing for Luye Pharma’s antidepressant drug LY03005 accepted by the U.S. FDA (Luye Press Release)
"Luye Pharma Group...announced that the U.S. Food and Drug Administration (FDA) has reviewed and accepted the filing of a New Drug Application (NDA) for LY03005, a new chemical drug for the treatment of major depressive disorder....Luye Pharma has obtained patents covering the chemical compound, crystal form and formulation of LY03005. The patents relating to the chemical compound and crystal form have been granted in target markets such as China, the U.S., Europe, Japan and Korea."
NDA • Patent
Ruoxinlin (toludesvenlafaxine extended release)